1 citations,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
Lupus nephritis patients face more challenges in family planning, work, symptoms, medication, and quality of life than those without it.
November 2017 in “Journal of Surgical Academia” Visual field defects in lupus nephritis can be caused by hypertensive retinopathy, not glaucoma or medication toxicity.
86 citations,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
2 citations,
January 2012 in “PubMed” The study evaluated the efficacy of mycophenolate mofetil (MMF) in treating juvenile onset severe lupus nephritis. Twelve children (mean age 12.6 years) underwent 6 months of induction therapy with MMF and prednisolone, resulting in significant improvements in urine protein, serum anti-double-stranded DNA antibody, renal function, albumin, and serum C3 and C4 levels (p < 0.05). Ten children continued with 18 months of maintenance therapy, during which no renal flares occurred, and the mean prednisolone dose was reduced to 9.2 mg/day. Among 5 patients who had a second biopsy, 4 showed significant histological improvement. Major infections were reported in 5 patients, including Herpes zoster, bacteremia, and hair loss. MMF was concluded to be an effective therapy for this condition.